Aripiprazole Tablet
Product Images NDC 72789-462

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 72789-462). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (72789462)

This text is a warning label for a medication called Aripiprazole, which may cause drowsiness and caution is advised while driving or performing tasks requiring mental alertness. It also includes dosage and storage instructions, details about the tablets' strength and quantity, as well as an expiration date. It further instructs the consumer to contact their doctor for advice on potential side effects and specifies the recommended frequency for taking the tablet(s) daily.*

FDA Label Image

Figure1 (Figure1)

This text provides information on the effect of various drugs on the pharmacokinetics of Aripiprazole. It lists the impact of CYP3A4 inhibitors, gastric acid blockers, and other drugs on Aripiprazole's bioavailability. The data includes changes in Aripiprazole's area under the curve (AUC) with the interacting drugs compared to the reference state without interacting drugs.*

FDA Label Image

Figure2 (Figure2)

Effect of Other Drugs on Aripipre: Different medications can have an impact on the effectiveness of Aripiprazole. Some drugs can inhibit its action, others act as inducers, some interact with Cytochrome P450 enzymes, while gastric acid blockers may affect its absorption. It is important to understand how these drugs interact to ensure the desired therapeutic effect. Reference changes may vary up to 20% when considering drug interactions.*

FDA Label Image

Figure3 (Figure3)

FDA Label Image

Figure4 (Figure4)

This text provides information on special populations for evaluating pharmacokinetics. It includes details related to age, gender, hepatic impairment, renal impairment, and the effect of aripiprazole on different parameters. The text also mentions poor metabolizers and provides ranges for age groups.*

FDA Label Image

Figure5 (Figure5)

FDA Label Image

Figure6 (Figure6)

FDA Label Image

Figure7 (Figure7)

FDA Label Image

Figure8 (Figure8)

FDA Label Image

Figure9 (Figure9)

The text provides information on the least squares mean change in the YGTSS total TIC score for different treatment groups, including ABILIFY LOW, ABILIFY HIGH, and PLACEBO, from baseline. This data can be useful for analyzing the efficacy of these treatments on TIC symptoms over time.*

FDA Label Image

Structure-1 (Structure 1)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.